On the 25th, Daewon Pharmaceutical announced that its nonsteroidal anti-inflammatory drug, ‘Pelubi CR Tab’ has entered the Indonesian market.

Daewon Pharmaceutical signed an exclusive export agreement with its Indonesian partner, PT. Interbat Pharmaceutical Industry, to export its finished Pelubi CR Tablet products to Indonesia. The 5-year deal is worth a total of USD 3 million (KRW 4 billion).

Pelubi CR tablet is an improved version of Daewon’s new drug ‘Pelubi’ that offers improved convenience in administration. After being released in 2015 as an anti-inflammatory analgesic in 2012, its prescription area has been expanded, adding various indications such as post-traumatic pain and